The gift of ADT (androgen deprivation) for advanced prostate cancer is a longer life. The harms caused by that same ADT are myriad and have been well discussed here. Included in those range of effects from very low testosterone is a powerful tendency to put on body fat. And to lose muscle mass and strength (sarcopenia).
We can all agree that the best way to combat this is through a dedicated exercise program including generous helpings of endurance exercise at mild to moderate intensities to burn fat and maintain cardiovascular fitness. And regular weight-lifting or equivalent resistance training to maintain muscle strength and mass in all the major muscle groups and core. And this must be enjoined with some type of nutritional balance, some personal diet that provides good complete nutrition while avoiding excesses and harmful patterns. Again, it has been much discussed here. There is no one right approach for it involves many individual factors.
This can be hard to maintain while on ADT but it is necessary and brings substantial rewards in well being and QOL.
However, for very many of us it is not enough to keep excess fat from accumulating. Resulting in overweight, over-fat (Body Mass index above 27), or obesity (BMI >30). This, in turn can lead to Metabolic Syndrome, Pre-Diabetes and Type 2 Diabetes (T2DM). This is a terribly costly and slippery slope that robs health.
I should list the diagnostic criteria for Metabolic Syndrome: It exists when any 3 of the following 5 criteria are present. 1) Abdominal obesity (waist >40 inches in men or BMI>25). 2) High blood pressure over 130 sys / 80 dias, or on BP Med. 3) Elevated fasting glucose 0ver 100. 4) Elevated Triglycerides >150. 5) HDL Cholesterol <40. Metabolic Syndrome also causes increased blood clot risks and is always associated with insulin-resistance.
There has been a fairly recent revolution in the management of T2DM and pre-diabetes. For many decades the first treatment of choice has been Metformin, one of the safest and least expensive medicines in all the world. If that proved insufficient fro DM control there were a variety of other meds to try, then ultimately on to injectable insulin. The entire picture changed with the bioengineering of a new class of medications, especially: Semaglutide. Semaglutide is a GLP-1 receptor agonist. Glucagon-Like-Peptide 1 receptor. It has revolutionized treatment for T2DM. You have seen the ads, it is marketed as Rybelsus in an oral weekly pill form, and as Ozembic in a once weekly injection.
And Semaglutide causes weight loss, fat loss very efficiently and predictably. This has now been confirmed in clinical trials in non-diabetics for obesity or overweight (BMI>27). And it does it with a great safety and side effect profile. That is the wonderful news and why I am now suggesting that it be considered for those with APC on ADT who have become overweight or obese and are on that spectrum leading to Metabolic Syndrome and T2DM.
The mechanisms of action of GPL-1R agonists are to increase insulin secretion; Thus increase sugar metabolism reducing blood glucose; Inhibits Glucagon (the anti-insulin); Decreases Appetite; And also slows gastric emptying. These all add up to a healthier metabolism profile and fat/weight loss.
The article linked was in NEJM in March 2021:
Once-Weekly Semaglutide in Adults with Overweight
or Obesity
nejm.org/doi/full/10.1056/N...
They randomized 1306 overweight or obese patients to Semaglutide 2.4 mg orally weekly, and 655 to placebo. Assessment at over one year (68 weeks) showed a mean 15% weight loss in the Semaglutide group. Side effects were mild, most commonly mild GI upset or nausea. You can read the details and discuss with your physicians. It could be a game changer, at least for this aspect of our lives and treatments. Paul